- Independent clinical trial finds probiotic strains used in Biome Australia’s (BIO) Breathe Probiotic improves symptoms of asthma in children
- The Probiotic in Pediatric Asthma Management study found children who took the probiotics experienced 64.2 per cent fewer exacerbations of asthma symptoms
- The results have been published in the Journal of Immunology Research
- With the probiotics already available in Australian pharmacies, company MD Blair Norfolk says the trial validation provides significant commercial opportunities
- Shares were 9.5 per cent higher at 11.5 cents
The probiotic strains used in Biome Australia’s (BIO) Breathe Probiotic have been shown to improve symptoms of asthma in children in a clinical trial.
It is one of the first probiotics globally to show an improvement in asthma symptoms.
The Probiotic in Pediatric Asthma Management study was completed in Italy to assess the efficacy of two specific probiotic strains, L. salivarius LS01 and B. breve B632, which are both in Biome’s Breath Probiotic, in reducing the symptoms of asthma.
According to the authors of the study, an increase in asthma prevalence is attributed to the hygiene hypothesis, especially to the imbalance of human microbiota composition, abundance and diversity.
The randomised placebo-controlled double-blind clinical trial involved 422 children and ran over an eight-week period. It found that the group of children who took the combination of probiotic strains experienced 64.2 per cent fewer exacerbations of their asthma symptoms, compared to the group who took a placebo.
The authors said: “The finding that probiotic strains… can reduce asthma exacerbations in children provides a potential complementary therapy for primary care physicians”.
The results have been published in the Journal of Immunology Research.
Biome said the data clinically validates its Breathe Probiotic product which is available in Australian pharmacies and through independent health practitioners.
Biome Australia Managing Director and Founder Blair Norfolk said the evidence is a major milestone for the company and the health industry.
“The clinical validation provides significant commercial opportunities for us to work closely with and expand our network of healthcare practitioners to improve the quality of life for asthma patients,” he said.
Company shares were trading 9.5 per cent higher at 11.5 cents at 3.05pm AEDT.